Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.
Identifieur interne : 000433 ( PubMed/Curation ); précédent : 000432; suivant : 000434Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.
Auteurs : S D Lawn [États-Unis] ; R J Shattock ; J W Acheampong ; R B Lal ; T M Folks ; G E Griffin ; S T ButeraSource :
- AIDS (London, England) [ 0269-9370 ] ; 1999.
Descripteurs français
- KwdFr :
- Antigènes HLA-DR (immunologie), Antituberculeux (usage thérapeutique), Charge virale, Facteur de nécrose tumorale alpha (métabolisme), Ghana, Humains, Infections opportunistes liées au SIDA (immunologie), Infections opportunistes liées au SIDA (traitement médicamenteux), Infections opportunistes liées au SIDA (virologie), Tuberculose (), Tuberculose (immunologie), Tuberculose (traitement médicamenteux), Tuberculose (virologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification).
- MESH :
- immunologie : Antigènes HLA-DR, Infections opportunistes liées au SIDA, Tuberculose.
- isolement et purification : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- métabolisme : Facteur de nécrose tumorale alpha.
- traitement médicamenteux : Infections opportunistes liées au SIDA, Tuberculose.
- usage thérapeutique : Antituberculeux.
- virologie : Infections opportunistes liées au SIDA, Tuberculose.
- Charge virale, Ghana, Humains, Tuberculose.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- AIDS-Related Opportunistic Infections (drug therapy), AIDS-Related Opportunistic Infections (immunology), AIDS-Related Opportunistic Infections (virology), Antitubercular Agents (therapeutic use), Ghana, HIV-1 (isolation & purification), HLA-DR Antigens (immunology), Humans, Tuberculosis (complications), Tuberculosis (drug therapy), Tuberculosis (immunology), Tuberculosis (virology), Tumor Necrosis Factor-alpha (metabolism), Viral Load.
- MESH :
- chemical , immunology : HLA-DR Antigens.
- chemical , metabolism : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antitubercular Agents.
- geographic : Ghana.
- complications : Tuberculosis.
- drug therapy : AIDS-Related Opportunistic Infections, Tuberculosis.
- immunology : AIDS-Related Opportunistic Infections, Tuberculosis.
- isolation & purification : HIV-1.
- virology : AIDS-Related Opportunistic Infections, Tuberculosis.
- Humans, Viral Load.
Abstract
To determine the impact of treatment of tuberculosis on plasma HIV-1 load in African subjects and to correlate viral load with response to treatment and changes in immune activation.
PubMed: 10563708
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000433
Links to Exploration step
pubmed:10563708Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.</title><author><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S D" last="Lawn">S D Lawn</name><affiliation wicri:level="1"><nlm:affiliation>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30333, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30333</wicri:regionArea></affiliation></author><author><name sortKey="Shattock, R J" sort="Shattock, R J" uniqKey="Shattock R" first="R J" last="Shattock">R J Shattock</name></author><author><name sortKey="Acheampong, J W" sort="Acheampong, J W" uniqKey="Acheampong J" first="J W" last="Acheampong">J W Acheampong</name></author><author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R B" last="Lal">R B Lal</name></author><author><name sortKey="Folks, T M" sort="Folks, T M" uniqKey="Folks T" first="T M" last="Folks">T M Folks</name></author><author><name sortKey="Griffin, G E" sort="Griffin, G E" uniqKey="Griffin G" first="G E" last="Griffin">G E Griffin</name></author><author><name sortKey="Butera, S T" sort="Butera, S T" uniqKey="Butera S" first="S T" last="Butera">S T Butera</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10563708</idno><idno type="pmid">10563708</idno><idno type="wicri:Area/PubMed/Corpus">000433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000433</idno><idno type="wicri:Area/PubMed/Curation">000433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000433</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.</title><author><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S D" last="Lawn">S D Lawn</name><affiliation wicri:level="1"><nlm:affiliation>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30333, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30333</wicri:regionArea></affiliation></author><author><name sortKey="Shattock, R J" sort="Shattock, R J" uniqKey="Shattock R" first="R J" last="Shattock">R J Shattock</name></author><author><name sortKey="Acheampong, J W" sort="Acheampong, J W" uniqKey="Acheampong J" first="J W" last="Acheampong">J W Acheampong</name></author><author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R B" last="Lal">R B Lal</name></author><author><name sortKey="Folks, T M" sort="Folks, T M" uniqKey="Folks T" first="T M" last="Folks">T M Folks</name></author><author><name sortKey="Griffin, G E" sort="Griffin, G E" uniqKey="Griffin G" first="G E" last="Griffin">G E Griffin</name></author><author><name sortKey="Butera, S T" sort="Butera, S T" uniqKey="Butera S" first="S T" last="Butera">S T Butera</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="ISSN">0269-9370</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS-Related Opportunistic Infections (drug therapy)</term><term>AIDS-Related Opportunistic Infections (immunology)</term><term>AIDS-Related Opportunistic Infections (virology)</term><term>Antitubercular Agents (therapeutic use)</term><term>Ghana</term><term>HIV-1 (isolation & purification)</term><term>HLA-DR Antigens (immunology)</term><term>Humans</term><term>Tuberculosis (complications)</term><term>Tuberculosis (drug therapy)</term><term>Tuberculosis (immunology)</term><term>Tuberculosis (virology)</term><term>Tumor Necrosis Factor-alpha (metabolism)</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antigènes HLA-DR (immunologie)</term><term>Antituberculeux (usage thérapeutique)</term><term>Charge virale</term><term>Facteur de nécrose tumorale alpha (métabolisme)</term><term>Ghana</term><term>Humains</term><term>Infections opportunistes liées au SIDA (immunologie)</term><term>Infections opportunistes liées au SIDA (traitement médicamenteux)</term><term>Infections opportunistes liées au SIDA (virologie)</term><term>Tuberculose ()</term><term>Tuberculose (immunologie)</term><term>Tuberculose (traitement médicamenteux)</term><term>Tuberculose (virologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HLA-DR Antigens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes HLA-DR</term><term>Infections opportunistes liées au SIDA</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antituberculeux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Charge virale</term><term>Ghana</term><term>Humains</term><term>Tuberculose</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine the impact of treatment of tuberculosis on plasma HIV-1 load in African subjects and to correlate viral load with response to treatment and changes in immune activation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10563708</PMID><DateCreated><Year>1999</Year><Month>11</Month><Day>23</Day></DateCreated><DateCompleted><Year>1999</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0269-9370</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>16</Issue><PubDate><Year>1999</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.</ArticleTitle><Pagination><MedlinePgn>2231-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the impact of treatment of tuberculosis on plasma HIV-1 load in African subjects and to correlate viral load with response to treatment and changes in immune activation.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Clinical and microbiological responses, immune activation parameters and plasma HIV-1 load were determined in 20 patients with pulmonary tuberculosis and HIV-1 coinfection in Ghana, West Africa during the first 3 months of anti-tuberculosis treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma HIV-1 load and markers of immune activation were determined by commercially available assays. Human leukocyte antigen (HLA)-DR incorporation into the HIV-1 envelope was measured by using an immunomagnetic capture technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment of tuberculosis resulted in significant improvements in weight and haemoglobin, a high sputum smear conversion rate and marked reductions in mean plasma tumour necrosis factor (TNF) receptor-1, interleukin-6 and C-reactive protein. Furthermore, incorporation of host HLA-DR into the HIV-1 envelope decreased; this also suggested a reduction in immune activation of the cells supporting viral replication. However, of importance with regard to AIDS pathogenesis, neither mean plasma TNF-alpha nor HIV-1 load decreased significantly.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The failure of HIV-1 plasma load to decline significantly during the initial months of anti-tuberculosis treatment is associated with high, sustained systemic levels of TNF-alpha. The dissociation between the sustained levels of plasma TNF-alpha and the major reductions in other, diverse immune activation parameters may represent dysregulation of cytokine production in these African patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lawn</LastName><ForeName>S D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shattock</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Acheampong</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Folks</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Butera</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017088" MajorTopicYN="N">AIDS-Related Opportunistic Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10563708</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000433 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000433 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:10563708
|texte= Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:10563708" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |